{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:10:48Z","timestamp":1785892248910,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020812","name":"Robert K Steel Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020402","name":"Y-mAbs Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.xcrm.2025.102040","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:26:33Z","timestamp":1743251193000},"page":"102040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1788-1512","authenticated-orcid":false,"given":"Nicole","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Veach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Cheal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett M.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102040_bib1","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","article-title":"Peritoneal carcinomatosis","volume":"19","author":"Coccolini","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2025.102040_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1148\/rg.292085189","article-title":"Secondary tumors and tumorlike lesions of the peritoneal cavity: imaging features with pathologic correlation","volume":"29","author":"Levy","year":"2009","journal-title":"Radiographics"},{"key":"10.1016\/j.xcrm.2025.102040_bib3","doi-asserted-by":"crossref","first-page":"5643s","DOI":"10.1158\/1078-0432.CCR-07-0985","article-title":"Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer","volume":"13","author":"Meredith","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102040_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-7800-2-3","article-title":"Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer","volume":"2","author":"Harmon","year":"2005","journal-title":"Int. Semin. Surg. Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.xcrm.2025.102040_bib6","first-page":"143","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future","volume":"7","author":"Dehal","year":"2016","journal-title":"J.\u00a0Gastrointest. Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib7","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jso.27223","article-title":"Incomplete cytoreductive surgery for appendiceal and colorectal peritoneal carcinomatosis: Characteristics and outcomes of an overlooked group","volume":"127","author":"Goffredo","year":"2023","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib8","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J.\u00a0Gastrointest. Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib10","article-title":"Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico","volume":"2011","author":"L\u00f3pez-Basave","year":"2011","journal-title":"Int. Sch. Res. Not."},{"key":"10.1016\/j.xcrm.2025.102040_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/00015458.2014.11681046","article-title":"Clinical Value of (18)F-FDG- PET-CT in the Preoperative Staging of Peritoneal Carcinomatosis from Colorectal Origin","volume":"114","author":"De Vos","year":"2014","journal-title":"Acta Chir. Belg."},{"key":"10.1016\/j.xcrm.2025.102040_bib12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1245\/s10434-009-0387-7","article-title":"(18)F-FDG-PET\/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"16","author":"Pfannenberg","year":"2009","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00261-007-9211-7","article-title":"Staging of peritoneal carcinomatosis: enhanced CT vs. PET\/CT","volume":"33","author":"Dromain","year":"2008","journal-title":"Abdom. Imaging"},{"key":"10.1016\/j.xcrm.2025.102040_bib14","article-title":"Neoadjuvant immunotherapy of locoregionally advanced solid tumors","volume":"10","author":"Ahmad","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.xcrm.2025.102040_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2009.05.035","article-title":"Endoradiotherapy in cancer treatment--basic concepts and future trends","volume":"625","author":"Zoller","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102040_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/07357908409040313","article-title":"Radioimmunodetection and radioimmunotherapy","volume":"2","author":"Larson","year":"1984","journal-title":"Cancer Invest."},{"key":"10.1016\/j.xcrm.2025.102040_bib17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting: A Path Forward for Radioimmunotherapy","volume":"63","author":"Sarah","year":"2022","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/imt.13.20","article-title":"Radioimmunotherapy for peritoneal cancers","volume":"5","author":"Seidl","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.xcrm.2025.102040_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1440-1673.1999.00717.x","article-title":"Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer","volume":"43","author":"Allen","year":"1999","journal-title":"Australas. Radiol."},{"key":"10.1016\/j.xcrm.2025.102040_bib20","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: In\u00a0vitro, in\u00a0vivo and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2025.102040_bib22","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1245\/s10434-008-0070-4","article-title":"The Effects of Adjuvant Experimental Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy on Intestinal and Abdominal Healing after Cytoreductive Surgery for Peritoneal Carcinomatosis in the Rat","volume":"15","author":"Aarts","year":"2008","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib23","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1245\/s10434-007-9509-2","article-title":"A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats","volume":"14","author":"Aarts","year":"2007","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7290.2014.00008","article-title":"Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model","volume":"13","author":"Muselaers","year":"2014","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.xcrm.2025.102040_bib25","doi-asserted-by":"crossref","first-page":"28935","DOI":"10.18632\/oncotarget.25649","article-title":"Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts","volume":"9","author":"Yoshii","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102040_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4103\/jcrt.JCRT_124_20","article-title":"Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with (64)Cu-labeled cetuximab against peritoneal dissemination of gastric cancer in a mouse model","volume":"18","author":"Tachibana","year":"2022","journal-title":"J.\u00a0Cancer Res. Therapeut."},{"key":"10.1016\/j.xcrm.2025.102040_bib27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2967\/jnumed.118.225045","article-title":"(64)Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer","volume":"60","author":"Yoshii","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib28","doi-asserted-by":"crossref","first-page":"14591","DOI":"10.1039\/C7DT01819C","article-title":"Comparative studies on the therapeutic benefit of targeted \u03b1-particle radiation therapy for the treatment of disseminated intraperitoneal disease","volume":"46","author":"Milenic","year":"2017","journal-title":"Dalton Trans."},{"key":"10.1016\/j.xcrm.2025.102040_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fmed.2015.00088","article-title":"Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis","volume":"2","author":"Derrien","year":"2015","journal-title":"Front. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib30","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.208611","article-title":"Radiolabeled Antibodies Against M\u00fcllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer","volume":"59","author":"Deshayes","year":"2018","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2017.01.003","article-title":"B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models","volume":"47","author":"Kasten","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.xcrm.2025.102040_bib32","first-page":"441","article-title":"Evaluation of platinum chemotherapy in combination with HER2-targeted \u03b1-particle radiation","volume":"28","author":"Milenic","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.xcrm.2025.102040_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/19420862.2014.985160","article-title":"Evaluation of cetuximab as a candidate for targeted \u03b1-particle radiation therapy of HER1-positive disseminated intraperitoneal disease","volume":"7","author":"Milenic","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2025.102040_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069613","article-title":"Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb","volume":"8","author":"Boudousq","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102040_bib35","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/cas.13282","article-title":"Locoregional therapy with \u03b1-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice","volume":"108","author":"Li","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2025.102040_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102040_bib37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7150\/thno.3582","article-title":"Pretargeted molecular imaging and radioimmunotherapy","volume":"2","author":"Goldenberg","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2025.102040_bib52","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study","volume":"38","author":"Modak","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib53","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2967\/jnumed.121.262793","article-title":"Biodistribution and Radiation Dosimetry of Intraperitoneally Administered 124I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors","volume":"63","author":"Milan","year":"2022","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/1535-7163.MCT-21-0353","article-title":"Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis","volume":"21","author":"Chandler","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2025.102040_bib39","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1158\/1078-0432.CCR-05-0607","article-title":"Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein","volume":"11","author":"Buchsbaum","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102040_bib40","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.7150\/thno.35461","article-title":"Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept","volume":"9","author":"Rondon","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2025.102040_bib41","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2967\/jnumed.112.106278","article-title":"Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer","volume":"53","author":"Schoffelen","year":"2012","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib42","first-page":"1211","article-title":"Pretargeted Radioimmunotherapy using 225Ac for Intraperitoneal GPA33-Expressing Colorectal Xenografts","volume":"61","author":"Christopher","year":"2020","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-20-2150","article-title":"A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy","volume":"27","author":"Santich","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102040_bib44","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.7150\/thno.48810","article-title":"Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses","volume":"10","author":"Cheal","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2025.102040_bib45","series-title":"Ac-225 Delivered by Self-Assembling Dis-Assembling (SADA) Bispecific Antibodies Ablates Colorectal and Appendiceal Peritoneal Xenografts with Minimal Toxicity, Advanced Cancer Therapies","author":"Aguirre KL","year":"2025"},{"key":"10.1016\/j.xcrm.2025.102040_bib46","first-page":"108","article-title":"Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model","volume":"28","author":"Frost","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.xcrm.2025.102040_bib47","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2967\/jnumed.116.178327","article-title":"Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated \u03b1-Radioimmunotherapy with (211)At-MX35-F(ab')(2): Influence of Absorbed Tumor Dose and Effect on Long-Term Survival","volume":"58","author":"B\u00e4ck","year":"2017","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib48","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2967\/jnumed.114.143842","article-title":"Dose escalation and dosimetry of first-in-human \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab","volume":"55","author":"Meredith","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib49","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and Outcome Measures of First-in-Human Intraperitoneal \u03b1 Radioimmunotherapy With 212Pb-TCMC-Trastuzumab","volume":"41","author":"Meredith","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102040_bib50","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2015.07.005","article-title":"Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients","volume":"93","author":"Cederkrantz","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.xcrm.2025.102040_bib54","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/ph8030416","article-title":"Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial","volume":"8","author":"Milenic","year":"2015","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xcrm.2025.102040_bib55","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2967\/jnumed.117.201285","article-title":"Model of Intraperitoneal Targeted \u03b1-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes","volume":"59","author":"Palm","year":"2018","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2025.102040_bib56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2967\/jnumed.121.263349","article-title":"Estimating the Risk for Secondary Cancer After Targeted \u03b1-Therapy with (211)At Intraperitoneal Radioimmunotherapy","volume":"64","author":"Leidermark","year":"2023","journal-title":"J.\u00a0Nucl. Med."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:39:35Z","timestamp":1769056775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666379125001132"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102040","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102040"}}